John H. Johnson
Lead Independent Director, Board of Directors
Mr. Johnson became our Lead Independent Director in January 2016 and has been a Director of Sucampo since December 2014. He most recently served as the President and Chief Executive Officer of Dendreon Corporation, a biotechnology company focused on cancer, from 2012 to July 2014. Prior to Dendreon, Mr. Johnson served as the Chief Executive Officer of Savient Pharmaceuticals, Inc., from 2011 to 2012, and as President of Eli Lilly & Company’s Oncology Unit following its 2008 acquisition of Imclone Systems, Inc. He previously held executive roles of increasing responsibility at Johnson & Johnson, where he worked from 1988 to 2007.
Mr. Johnson is currently the Chairman of the Board of Directors of Cortendo AB, a global biopharmaceutical company focused on orphan endocrine disorders. He also serves as a member of the Board of Directors of Cempra Inc., a clinical-stage pharmaceutical company, Portola Pharmaceuticals, Inc., a biopharmaceutical company, and Histogenics Corporation, a regenerative medicine company. Previously, he served as a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO).
Mr. Johnson earned a bachelor’s degree from East Stroudsburg University of Pennsylvania.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.